Experts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.
Ezra Cohen, MD
Advertisement
Articles by Ezra Cohen, MD
Advertisement
Latest Updated Articles
Immunotherapeutic Approaches to the Management of Head and Neck CancerPublished: December 17th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology
3
FDA Approves Revumenib in R/R NPM1-Mutant AML
4
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
5
